Rx00055 - Canakinumab


Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00055
Primary Indication
Secondary Indication

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
systemic juvenile idiopathic arthritis systemic onset juvenile idiopathic arthritis 352 352 352 11462.852 0 0.0
Cryopyrin-Associated Periodic Syndromes cryopyrin-associated periodic syndromes 1129 1129 1129 3573.892 0 0.0

Chemical, Pharmacological and Biological Annotations


ATC Code:
L04AC08
Categories:
Anti-Inflammatory Agents; Monoclonal antibodies
KEGG Drug ID:
D09315
Classification:
Kingdom:
Organic Compounds
Superclass:
Organic Acids
Class:
Carboxylic Acids and Derivatives
Subclass:
Amino Acids, Peptides, and Analogues
Indication:
Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of ...
Click to show more...
Pharmacodynamics:
Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pha...
Click to show more...
Description:
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-resi...
Click to show more...
Mechanism:
In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1β) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1β, and mutations in cryopyr...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Not Available from DrugBank


Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org